RAC - Charts & Price Action, page-19327

but do we need to be planning and positioning the company like we are or could if we wanted to go all the way? (for market recognition, and buyout bargaining position).
Does the market think we’re putting all our eggs in a the buyout basket and backing the company into a corner and desperately holding up the for sale sign.

while the above worries me somewhat I think Bisantrene will prove the potential we all see and will be in hot demand, so above will be less of an issue at that time, the problem I see is what happens till then?

while the share price decline over last few years has been disappointing, and cause for much friction with holder, i personally think it has less to do with anything happening at the company level and more to do with the wider world issues. Only have to look around at other pre-revenue companies in development phase to see most have a very similar chart to Race.

With inflation continuing to ease, once interest rates start to decline coinciding with RC220 delivery and clinical progress this alignment should bring traction to continued reversal and building momentum towards achieving sp goals.